In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

PHILADELPHIA -- Meticulous positioning matters in reducing stroke risk after left ventricular assist device (LVAD) placement, according to a researcher here. Two parameters of multi-detector cardiac ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

NEW ORLEANS, LA—Final, full results from the MOMENTUM 3 trial show that the HeartMate 3 magnetically levitated, centrifugal-flow left ventricular assist device (LVAD) is superior to the ...

CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...

Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump as a key factor in boosting 2012 first-quarter revenue 27% versus a year earlier. As ...

Please provide your email address to receive an email when new articles are posted on . Patients who received a new-generation left ventricular assist device experienced fewer ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...

March 12 (UPI) --The HeartMate 3, an update to one of the most widely-used left ventricle assist devices, or LVADs, in the world, showed strong long-term results during a large clinical trial, its ...